Crawford Nigel W, Heath John A, Ashley David, Downie Peter, Buttery Jim P
NHMRC Centre for Clinical Research Excellence in Child and Adolescent Immunization, Parkville, VIC, Australia.
Pediatr Blood Cancer. 2010 Jan;54(1):128-33. doi: 10.1002/pbc.22256.
Survivors of childhood and adolescent cancer are at risk of vaccine preventable diseases and are recommended to receive booster vaccinations post-chemotherapy. The aim of this study was to describe the compliance of post-chemotherapy revaccination of childhood cancer survivors relative to current Australian guidelines.
A multi-faceted retrospective review of childhood cancer survivors at the Royal Children's Hospital, Melbourne, Australia was undertaken. Immunisation status was reviewed through four sources: (1) hospital records; (2) telephone survey of consenting participants; (3) Australian Childhood Immunization Register (ACIR); and (4) family practitioners immunisation records. Participants were 0-18 years, and at least 6 months post-treatment for their cancer.
The study was conducted between March and September 2006. Eighty-nine patients with a median age at diagnosis of 5.3 years were included, 56% of patients had a diagnosis of leukaemia and 44% solid tumours. The median duration since completion of therapy was 3.1 years. Reviewing all sources, 39% (35/89) of participants had no evidence of booster vaccinations post-completion of therapy. Younger age (P = 0.001), and those diagnosed with leukaemia (P = 0.04) were more likely to have received at least one booster vaccine. Forty-seven percent (42/89) had received at least one influenza vaccination.
This study highlights poor compliance with current guidelines for re-vaccination in survivors of childhood and adolescent cancer. More evidence is required and these re-vaccination guidelines need to take into account treatment intensity. Multi-component strategies are essential to ensure protection from vaccine preventable diseases in this population.
儿童和青少年癌症幸存者面临疫苗可预防疾病的风险,建议在化疗后接种加强疫苗。本研究的目的是描述儿童癌症幸存者化疗后再次接种疫苗相对于澳大利亚现行指南的依从性。
对澳大利亚墨尔本皇家儿童医院的儿童癌症幸存者进行了多方面的回顾性研究。通过四个来源审查免疫状况:(1)医院记录;(2)对同意参与的参与者进行电话调查;(3)澳大利亚儿童免疫登记册(ACIR);(4)家庭医生免疫记录。参与者年龄在0至18岁之间,且癌症治疗后至少6个月。
该研究于2006年3月至9月进行。纳入了89例诊断时中位年龄为5.3岁的患者,56%的患者诊断为白血病,44%为实体瘤。治疗结束后的中位持续时间为3.1年。审查所有来源后,39%(35/89)的参与者在治疗结束后没有加强疫苗接种的证据。年龄较小(P = 0.001)以及诊断为白血病的患者(P = 0.04)更有可能接种至少一剂加强疫苗。47%(42/89)的患者接种了至少一剂流感疫苗。
本研究突出了儿童和青少年癌症幸存者对当前再次接种疫苗指南的依从性较差。需要更多证据,并且这些再次接种疫苗指南需要考虑治疗强度。多成分策略对于确保该人群免受疫苗可预防疾病的侵害至关重要。